A. Oliver Sartor, MD, presented “PSMA Radiopharmaceuticals: Update 2023” during the 26th Annual Southwest Prostate Cancer Symposium conference on April 15, 2023, in Scottsdale, Arizona.
How to cite: Sartor, A. Oliver “PSMA Radiopharmaceuticals: Update 2023.” April 15, 2023. Accessed Nov 2024. https://grandroundsinurology.com/psma-radiopharmaceuticals-update-2023/
PSMA Radiopharmaceuticals: Update 2023 – Summary
Oliver Sartor, MD of Tulane University School of Medicine, presents on the use of prostate-specific membrane antigen (PSMA) radiopharmaceuticals in the treatment of prostate cancer in 2023. He provides a comprehensive overview of recent advancements, clinical applications, and future directions for PSMA-targeted therapies. He discusses the latest developments in PSMA-based imaging, highlighting the efficacy of PSMA PET/CT scans in detecting prostate cancer metastases with high sensitivity and specificity. Dr. Sartor emphasizes that these imaging techniques have revolutionized the staging and restaging of prostate cancer, enabling more accurate assessment of disease spread and guiding treatment decisions.
Dr. Sartor also covers therapeutic applications of PSMA radiopharmaceuticals, focusing on PSMA-targeted radioligand therapy (RLT). He presents data from recent clinical trials demonstrating the efficacy of PSMA RLT with agents such as lutetium-177 (Lu-177) PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC).
In conclusion, Dr. Sartor highlights the transformative impact of PSMA radiopharmaceuticals on the management of prostate cancer, underscoring the potential of PSMA-targeted radiopharmaceuticals to significantly enhance the detection and treatment of prostate cancer, offering new hope for patients with advanced disease.
About the 26th Annual Southwest Prostate Cancer Symposium:
This conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Dr. Sartor earned his MD from Tulane University School of Medicine in 1982. After training at the University of Pennsylvania and Tulane Medical School, he completed a fellowship at the National Cancer Institute, where he focused on advanced prostate cancer therapies. He held positions at LSU Medical School and LSU Health Sciences Center, directing oncology programs before joining Dana Farber Cancer Institute in 2006. In 2008, he returned to Tulane University as the C. E. and Bernadine Laborde Professor of Cancer Research.
An internationally recognized expert in prostate cancer, Dr. Sartor’s interests have focused broadly on prostate cancer, predominantly in those patients who failed initial therapies. His publications range from genetic studies on prostate cancer to clinical trials involving novel agents. He has been a lead author on two studies pivotal for FDA drug approval in prostate cancer and has been the PI or co-PI on a number of prospective international clinical trials evaluating new therapies for patients with advanced prostate cancer.
Having published over 500 scholarly articles and having served as the past Chairman of the Department of Defense Prostate Integration Panel, Dr. Sartor, in addition to being the C.E. and Bernadine Laborde Professor of Cancer Research in the Departments of Medicine and Urology, is the Medical Oncology Chair of the GU Committee of the NRG, the Assistant Dean for Oncology at Tulane University School of Medicine, the Medical Director of the Tulane Cancer Center, and the Editor-in-Chief of the peer-reviewed journal, Clinical Genitourinary Cancer. In addition, he is currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).
